ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma, Systemic"

  • Abstract Number: 1562 • ACR Convergence 2025

    Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study

    adela cristina sarbu1, Liubov Petelytska2, lorenzo tofani3, Gianluca Moroncini4, Alexandra Balbir-Gurman5, elisabetta zanatta6, Jörg Henes7, paolo airò8, Marco Matucci-Cerinic9, Ana Maria Gheorghiu10, antonella marcoccia11, branimir Anić12, Jelena Colic13, Daniel Furst14, julia Spierings15, Francesco Del Galdo16, Britta Maurer17, Anna-Maria Hoffmann-Vold18, Oliver Distler19 and Cosimo Bruni20, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Department of Rheumatology and Immunology, Bern University Hospital, University of Bern, Bern, Switzerland, bern, Swaziland, 2Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. • Dept Internal Medicine #3, Bogomolets National Medical University, Kyiv, Ukraine, Kyiv, Ukraine, 3Department of Statistics, Informatics and Applications, University of Florence, Florence, Italy, firenze, Italy, 4Department of Internal Medicine, Marche University Hospital, Clinica Medica, Ancona, Italy, Ancona, Italy, 5• Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Tecchnion, Haifa, Israel, Haifa, Israel, 6Padova University Hospital, Rheumatology Unit, Padova, Italy, padova, Italy, 7Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, 8Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, brescia, Italy, 9University San Raffaele Milano, Milano, Milan, Italy, 10Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, 11Centro di Riferimento Interdisciplinare per la Sclerosi Sistemica (CRIIS), Roma, Italy, rome, Italy, 12Department of Internal Medicine, Division of Clinical Immunology and Rheumatology, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Croatia, zagreb, Croatia, 13Institute of Rheumatology Belgrade, Belgrade, Serbia, Belgrade, Serbia, 14Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, 15Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, 16University of Leeds, Leeds, United Kingdom, 17Department of Rheumatology & Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 18Oslo University Hospital, Oslo, Norway, 19Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 20University of Zurich, Zurich, Switzerland

    Background/Purpose: Although most vasoactive vasodilating drugs (VVDs) exert anti-fibrotic effects in pre-clinical studies, randomized controlled trials assessing their efficacy in systemic sclerosis-associated interstitial lung disease…
  • Abstract Number: 0683 • ACR Convergence 2025

    Symptom-Based Clustering of Gastrointestinal Involvement in Systemic Sclerosis

    Ali Ayla1, Ernesto Calderon Martinez2, Meng Zhang3, Claudia Pedroza4, Bingrui Chen5, Ashish Balar5, Michael Hughes6, Silvia Bellando Randone7, Brian Skaug1, Maureen Mayes8, Shervin Assassi9 and Zsuzsanna McMahan10, 1UTHealth Houston Division of Rheumatology, Houston, TX, 2UTHealth Houston, Houston, 3UTHealth Houston Division of Rheumatology, Houston, 4UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, 5UTHealth Houston, Houston, TX, 6Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, 7University of Florence, Florence, Italy, 8UT Health Houston Division of Rheumatology, Houston, TX, 9Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 10UT Health Houston, Houston, TX

    Background/Purpose: Virtually all patients with systemic sclerosis (SSc) experience gastrointestinal (GI) manifestations over the course of their disease, affecting any region from the mouth to…
  • Abstract Number: 2472 • ACR Convergence 2025

    Digesting the data: tracking gastro-intestinal manifestations in systemic sclerosis over time

    Cosimo Bruni1, Jasmin Klöti2, Aurora Maria Tatu3, Lea Stamm2, Rucsandra Dobrota4, Muriel Elhai5, Mike Becker6, Sinziana Muraru7, Gesa Sauer8, Anna-Maria Hoffmann-Vold9, Oliver Distler10 and Carina Mihai11, 1University of Zurich, Zurich, Switzerland, 2Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3Department of Gastroenterology, University Hospital Zurich, University of Zurich, 8091, Switzerland, 4Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, 5University Hospital zurich, Zürich, Switzerland, 6Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, 7University of Zurich, University Hospital Zurich, Zürich, Switzerland, 8Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, zurich, Switzerland, 9Oslo University Hospital, Oslo, Norway, 10Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 11University Hospital Zurich, University of Zurich, Zurich, Switzerland

    Background/Purpose: Gastrointestinal (GI) involvement is among the most frequent organ manifestations in systemic sclerosis (SSc), yet the timing of presentation of GI manifestations remains incompletely…
  • Abstract Number: 1561 • ACR Convergence 2025

    Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion

    Carlos de la Puente-Bujidos1, Antia Garcia Fernandez2, Verónica García García1, Jesús Loarce3 and Sandra Garrote-Corral1, 1Ramón y Cajal University Hospital, Madrid, Spain, 2Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 3Ramón y Cajal University Hospital, Madrid, Spain

    Background/Purpose: In 2019 a European expert consensus suggested that all patients with systemic sclerosis (SSc) should be screened with HRCT for interstitial lung disease (ILD)…
  • Abstract Number: 0674 • ACR Convergence 2025

    Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis

    Ian Odell1, Crystal Cheung1, Megan Wu2, Stephanie Perez3, Agrani Dixit4, Cassandra van Horn3, Muhammad Hamdan5, Baran Gunes6, Sophia Kujawski7, Hyojeong Lee3, Annie Wang3, Denise Esserman8, Michael Zamani9, F. Perry Wilson3, John Onofrey3, Xenophon Papademetris3 and Monique Hinchcliff10, 1Yale University School of Medicine, New Haven, CT, 2Yale University School of Medicine, Greenville, 3Yale University School of Medicine, New Haven, 4Yale School of Medicine, New Haven, CT, 5Yale University School of Medicine, Mansfield, 6Yale University School of Medicine, Pompton Plains, NJ, 7The George Washington University, New Haven, CT, 8Yale University School of Public Health, New Haven, 9Independent Statistician, Washington D.C., 10Yale School of Medicine, Westport, CT

    Background/Purpose: Calcinosis cutis (CC) is a disabling skin condition associated with systemic sclerosis (SSc). Although many CC treatments including sodium thiosulfate (STS) have been proposed,…
  • Abstract Number: L01 • ACR Convergence 2024

    Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases

    Matthew Martin1, Erik Wilker1, Diana Gikunju1, Usha Narayanan1, Unnati Pandya1, Vijetha Prakash1, Ashley Edwards1, Sameer Kawatkar1, Tenghui Chen1, Ragunath Chandran1, Sai Sunder1, Sumathi Biradar1, Joerg Distler2, Alexandra Joseph1, Stephanos Ioannidis1 and Bhavatarini Vangamudi1, 1Exo Therapeutics, Cambridge, MA, 2Exo Therapeutics, Düsseldorf, Germany

    Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
  • Abstract Number: 0961 • ACR Convergence 2024

    Multi-omics Study of Systemic Sclerosis Immunoglobulins G Effects on Endothelial Cells: A Distinct Profile in Anti-Topoisomerase I Positive Patients

    Aurélien Chepy1, Solange Vivier2, Abderrahmane Elhannani2, Fabrice Bray3, Clément Chauvet4, Martin Figeac5, Lucile Guilbert4, Eric HACHULLA6, Christian Rolando3, Sylvain Dubucquoi4, David Launay4 and Vincent sobanski4, 1Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, Nord-Pas-de-Calais, France, 2Univ. Lille, Inserm, CHU Lille, U1286—INFINITE—Institute for Translational Research in Inflammation, Lille, France., Lille, France, 3Univ. Lille, CNRS, USR 3290 - MSAP - Miniaturisation pour la Synthèse l’Analyse et la Protéomique, F-59000 Lille, France, Lille, France, 4Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France., Lille, France, 5Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000 Lille, France, Lille, France, 6CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., LILLE, France

    Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease characterized by autoimmunity, fibrosis and vasculopathy. Antinuclear antibodies (ANA) are strong diagnostic and prognosis biomarkers…
  • Abstract Number: 1976 • ACR Convergence 2024

    Artificial Intelligence Analysis of HRCT Images Reflects Pulmonary Involvement in Systemic Sclerosis Interstitial Lung Disease

    Enrico De Lorenzis1, Lucy Elizabeth Thornton2, Stefano Di Donato3, Marco Minerba3, Lesley-Anne Bissell4, Riccardo Bixio5, Anand Devaraj6, Peter George7 and Francesco Del Galdo8, 1Catholic University of the Sacred Heart, Roma, Rome, Italy, 21. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, 31. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, 4Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5University of Verona, Verona, Verona, Italy, 6Department of Radiology, Royal Brompton Hospital, London, London, United Kingdom, 7Department of Interstitial Lung Disease, Royal Brompton Hospital London, London, United Kingdom, 8University of Leeds, Leeds, United Kingdom

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality and morbidity in systemic sclerosis (SSc) patients. Current functional, imaging, and clinical measures of…
  • Abstract Number: 2645 • ACR Convergence 2024

    Human NCF1-p.R90H Variant Promotes Pulmonary Fibrosis in the Bleomycin-induced Mouse Model and Systemic Sclerosis Patients via Expansion of SPP1+Monocytes-derived Macrophages

    Xinran Yuan1, Xiaodong Qin2, Kenji Takemoto1, Jian Zhao1, Matthew Sanderson1, Xue Xu1, Kristi L Helke3, Bethany Wolf4, Joel Guthridge5, Judith A James6, Xiaodong Zhou7, Shervin Assassi8, Carol Feghali-Bostwick4, Dandan Wang9, Lingyun Sun10 and Betty P Tsao1, 1Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 2Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China (People's Republic), 3Department of Comparative Medicine, Medical University of South Carolina, Charleston, SC, 4Medical University of South Carolina, Charleston, SC, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Division of Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 8UTHealth Houston Division of Rheumatology, Houston, TX, 9Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical Schoo, Nanjing, Jiangsu, China (People's Republic), 10Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China (People's Republic)

    Background/Purpose: We previously identified a systemic lupus erythematosus (SLE) causal risk variant, p.Arg90His (p.R90H, rs201802880) substitution encoded in neutrophil cytosolic factor 1 (NCF1), an essential component…
  • Abstract Number: 0967 • ACR Convergence 2024

    Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions

    Hadijat Makinde1, Miranda Gurra1, Salina Dominguez2, Matthew Dapas2, Tyler Therron2, Kathleen Aren3, Marie-Pier Tetreault2, Monique Hinchcliff4, Deborah Winter5 and Harris Perlman1, 1Northwestern University, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern University Division of Rheumatology, Chicago, IL, 4Yale School of Medicine, Westport, CT, 5Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with gastroesophageal reflux, leading to…
  • Abstract Number: 2196 • ACR Convergence 2024

    Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings

    Suzanne Li1, Natalia Vasquez-Canizares2, Clare Pain3, Marinka Twilt4, Amra Adrovic5, Abdulrahman Alrasheed6, Simone Appenzeller7, ADELE CIVINO8, narendra bagri9, Patricia Costa Reis10, Muserref Cucueoglu11, Fatma Dedeoglu12, samundeeswari Deepak13, Jianghong Deng14, Dalia El-Ghoneimy15, Ivan Foeldvari16, Fernando Garcia-Rodriguez17, Marija Jelusic18, Ankur Jindal19, Ozgur Kasapcopur20, Maria Katsicas21, Archana Khan22, Raju Khubchandani23, Meiping Lu24, Hanna Lythgoe25, edoardo marrani26, Giorgia Martini27, Takako Miyamae28, Tomo Nozawa29, Seza Ozen30, Lidia Rutkowska-Sak31, Sunil Sampath13, Dieneke Schonenberg-Meinema32, Hongmei Song33, Betul Sozeri34, Hayakazu Sumida35, Maria Teresa Terreri36, Kathryn Torok37, Seyma Turkmen38, Dilara Unal38, Gong Yinv39, Emily Willis25, Rongjun Zheng24 and Brian Feldman40, and Pediatric International Consortium for Scleroderma, 1Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, Hackensack, NJ, 2Children's Hospital at Montefiore, Bronx, NY, 3Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom, 4Alberta Children's Hospital, Calgary, AB, Canada, 5Koc University Hospital, Istanbul, Turkey, 6King Abdullah Specialized Children Hospital, Riyadh, Saudi Arabia, 7Unicamp, Campinas, SP, Brazil, 8Pediatric Rheumatology "Vito Fazzi" Hospital LECCE, LECCE, Italy, 9All India Institute of Medical Sciences, New Delhi, Delhi, India, 10Hospital de Santa Maria, Lisbon, Portugal, 11Hacettepe University, Ankara, Turkey, 12Boston Children's Hospital, Boston, MA, 13THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST, Newcastle upon Tyne, United Kingdom, 14Beijing Children's Hospital, Beijing, China, 15Children's Hospital, Ain Shams University, Cairo, Egypt, 16Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 17Universidad Autonoma de Nuevo Leon, Monterrey, NL, Mexico, 18University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 19Postgraduate Institute of Medical Education and Research, Chandigarh, India, 20Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, 21Hospital Garrahan, Buenos Aires, Argentina, 22SRCC Children's Hospital, Mumbai, India, Mumbai, India, 23The SRCC Children's Hospital, Mumbai, India, 24Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China (People's Republic), 25Royal Manchester Children's Hospital, Manchester, United Kingdom, 26Dipartimento Neurofarba, Università di Firenze, Firenze, Italy, 27University of Udine University Hospital Santa Maria della Misericordia, Udine, Italy, 28Tokyo Women's Medical University, Tokyo, Japan, 29Yokohama City University, Yokohama, Japan, 30Department of Pediatrics, Hacettepe University, Ankara, Turkey, 31National Institute of Geriatrics, Rheumatology and Rehabilitation, Warszawa, Poland, 32Amsterdam University Medical Center, Amsterdam, Netherlands, 33Peking Union Medical College Hospital, Beijing, China, 34University of Health Sciences, Istanbul, Turkey, 35The University of Tokyo, Tokyo, Japan, 36UNIFESP, São Paulo, SP, Brazil, 37Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 38University of Health Sciences, Umraniye Training and Research Hospital, Ankara, Turkey, 39Children's Hospital Affiliated to Fudan University, Shanghai, China (People's Republic), 40Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Despite the high morbidity and mortality risk associated with juvenile systemic sclerosis (jSSc), evidence to guide management is limited.  No jSSc clinical trials have…
  • Abstract Number: 2654 • ACR Convergence 2024

    Adapting and Testing a Cognitive Rehabilitation Intervention Tailored for People with Systemic Sclerosis: Acceptability, Feasibility, & Impact on Health-related Outcomes

    Yen Chen1, Mary Alore2, Dinesh Khanna1 and Susan Murphy3, 1University of Michigan, Ann Arbor, MI, 2Self-employed, TROY, MI, 3University of Michigan, Plymouth, MI

    Background/Purpose: Cognitive dysfunction affects up to 87% of individuals with systemic sclerosis (SSc), often significantly impairing their work and daily activities and exacerbating other symptoms…
  • Abstract Number: 1070 • ACR Convergence 2024

    Evaluating & Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients

    John Hickernell1 and Zineb Aouhab2, 1Loyola Univeristy Medical Center, Chicago, IL, 2Loyola University Medical Center, Oak Brook, IL

    Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) has been shown to decrease mortality. The American College of Radiology, European…
  • Abstract Number: 2200 • ACR Convergence 2024

    Whole Blood Transcriptome Profiling in Juvenile Systemic Sclerosis Patients Reveals Active Immune Upregulation and Enhanced Fibrotic Signature

    Rania Elbakri1, Amanda Robinson2, Anwesha Sanyal1 and Kathryn Torok3, 1University of Pittsburgh, pittsburgh, PA, 2University of Utah Health, Salt Lake City, UT, 3Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare chronic autoimmune disorder characterized by skin thickening and multisystem organ involvement, leading to significant morbidity. The pathogenesis…
  • Abstract Number: 2685 • ACR Convergence 2024

    Association Between Gastrointestinal Bacterial Species and Radiological Features of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD): A Multicenter Study from the SSc Microbiome Consortium Project

    Arissa Young1, Kristofer Andreasson2, Swapna Joshi3, Jen Labus3, Andrea Low Hsiu Ling4, vanessa smith5, Zsuzsanna McMahan6, Antonia Valenzuela Vergara7, Susanna Proudman8, Grace Kim3, Gracijela Bozovic2, Jonathan Goldin3, Ezinne Aja3, Jonathan Jacobs3 and Elizabeth Volkmann9, 1UCLA, Los Angeles, CA, 2Lund University, Lund, Sweden, 3UCLA, Los Angeles, 43Singapore General Hospital, Duke-NUS, Singapore, Singapore, 5Ghent University Hospital, Gent, Belgium, 6UTHealth Houston Division of Rheumatology, Houston, TX, 7Pontificia Universidad Catolica de Chile, Santiago, Chile, 8Royal Adelaide Hospital, Adelaide, Australia, 9University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles

    Background/Purpose: Variations in gastrointestinal (GI) microbial communities may influence the development of lung diseases. Patients with SSc-ILD have a unique intestinal microbial signature. To further…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 16
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology